Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
125.00    1.20 (0.97%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £304.27m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
31st Jan 202211:50 amRNSPRTC's Gelesis Launches Plenity Media Campaign
26th Jan 202212:02 pmRNSPRTC’s Akili to Become Public & $162M Funding
14th Jan 20227:00 amRNSPRTC's Gelesis to Debut on NYSE Today Ticker GLS
7th Jan 202212:00 pmRNSPureTech to Present at JPM Healthcare Conference
6th Jan 20227:00 amRNSLYT-100 Shows Improved AE Profile vs Pirfenidone
5th Jan 202212:05 pmRNSGelesis Adds to BOD & Declared Effective by SEC
20th Dec 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Dec 20217:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 202112:00 pmRNSPRTC Presents Data at ACNP Conference For LYT-300
7th Dec 202112:00 pmRNSPRTC's Lymphatic Platform Candidate Human Study
1st Dec 202112:10 pmRNSPRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 202112:10 pmRNSPRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 202112:00 pmRNSPRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 202112:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
12th Nov 202112:00 pmRNSPRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 202112:00 pmRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
10th Nov 20217:00 amRNSPRTC Receives $100M from Founded Entity Shares
9th Nov 202112:34 pmRNSKRTX and Zai Lab to Develop KarXT in Greater China
9th Nov 20217:00 amRNSPRTC Presents at Jefferies Healthcare Conference
1st Nov 202110:20 amRNSNew Research in Journal Nature on Gelesis Tech
1st Nov 20217:00 amRNSTotal Voting Rights
22nd Oct 20216:00 pmRNSHoldings in Company - TR-1 Correction Announcement
20th Oct 20214:35 pmRNSPrice Monitoring Extension
14th Oct 202112:01 pmRNSPRTC's Vedanta Appoints Chief Legal Officer
12th Oct 20217:00 amRNSAdditional Listing
5th Oct 20211:01 pmRNSVedanta Positive Phase 2 Data in C. Diff Infection
5th Oct 20211:00 pmRNSPRTC's Sonde Launches Mental Health Monitor
29th Sep 20211:01 pmRNSAkili/Shionogi Report Positive Ph2 Data in Japan
20th Sep 20214:02 pmRNSNew PureTech Research Published In Nature Journal
14th Sep 202112:00 pmRNSPRTC to Present at Oppenheimer Healthcare Summit
1st Sep 20217:00 amRNSTotal Voting Rights
24th Aug 20217:00 amRNSHalf-year Report
23rd Aug 202112:00 pmRNSPRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
17th Aug 20211:03 pmRNSAkili Deal Furthers Digital Medicine Leadership
13th Aug 202112:00 pmRNSPRTC Appoints Industry Veteran & Physician as CMO
11th Aug 202112:00 pmRNSPRTC Receives $6.5M; Imbrium to Develop LYT-503
3rd Aug 20217:00 amRNSNotice of Results
2nd Aug 20217:00 amRNSTotal Voting Rights
23rd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
22nd Jul 20211:03 pmRNSPRTC’s Akili Releases New Features for EndeavorRx
22nd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
21st Jul 202112:03 pmRNSPureTech’s Vedanta Raises $68M Series D Financing
19th Jul 202112:02 pmRNSPRTC’s Gelesis to Become Public Via Capstar SPAC
9th Jul 202112:00 pmRNSPRTC’s Vor Announces Collaboration with Janssen
8th Jul 20212:05 pmRNSPRTC’s Sonde Announces Collaboration With Qualcomm
7th Jul 202112:00 pmRNSPRTC BeiGene LYT-200 Clinical Trial Agreement
1st Jul 20217:00 amRNSTotal Voting Rights
30th Jun 202112:00 pmRNSPRTC’s Vedanta Announces New Data from IBD Study
28th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.